原发性肝癌综合治疗进展

祝普利; 尹超; 冯建龙

doi:10.3969/j.issn.1001-5256.2015.06.034

原发性肝癌综合治疗进展

DOI: 10.3969/j.issn.1001-5256.2015.06.034

陕西省第四人民医院普外科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2811
- HTML全文浏览量: 16
- PDF下载量: 663
- 被引次数: 0
出版历程
- 出版日期: 2015-06-20

Progress in comprehensive treatment of primary liver cancer

摘要

摘要: 目前原发性肝癌的治疗方法虽然很多,但肿瘤治疗的预后效果仍不理想。主要阐述了肝切除、肝移植、消融治疗、介入治疗、放射治疗、药物治疗及生物免疫等方法治疗原发性肝癌的进展,并对肝癌的多学科综合治疗方法进行了简要的介绍。认为综合治疗可以发挥各种治疗方法的优势,达到最好的治疗效果,是提高肝癌患者总体疗效的关键措施。
- 肝肿瘤 /
- 综合疗法 /
- 综述
Abstract: The therapeutic methods for the treatment of primary liver cancer is in abundant supply,yet the prognosis far from satisfactory.The article mainly introduces the progress in hepatectomy,liver transplantation,ablation therapy,interventional therapy,radiotherapy,drug therapy,and biological immunity in the treatment of primary liver cancer,and it also briefs us on the multidisciplinary and comprehensive treatment of primary liver cancer,believing that comprehensive treatment is the key to improving the overall response of primary liver cancer by giving full play to the superiority of each treatment and achieving the optimal therapeutic effect.
- liver neoplasms /
- combined modality therapy /
- review

HTML全文

参考文献(24)

[1]REGIMBEAU JM,KINMANESH R,FARGES O,et al.Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma[J].Sugery,2002,131(3):311-317.

[2]PANG RW,JOHN JW,JOHNSON PJ,et al.Biology of hepatocellular carcinoma[J].Ann Surg Oncol,2008,15(4):962-971.

[3]LEE KT,WANG SN,SU RW,et al.Is wider surgical margin justified for better clinical outcomes in patients with resectable hepatocellular carcinoma[J].J Formos Med Assoc,2012,111(3):160-170.

[4]LI HY,WEI YG,YAN LN,et al.Salvage liver transplantation in the treatment of hepatocellular carcinoma:a meta-analysis[J].World J Gastroenterol,2012,18(19):2415-2422.

[5]KULIK LM,FISHER RA,RODRIGO DR,et al.Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma:results of the A2ALL cohort[J].Am J Transplant,2012,12(11):2997-3007.

[6]BHANGUI P,VIBERT E,MAJNO P,et al.Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma:living versus deceased donor transplantation[J].Hepatology,2011,53(5):1570-1579.

[7]KIM YS,RHIM H,LIM HK,et al.Intraoperative radiofrequency ablation for hepatocellular carcinoma:long-term results in a large series[J].Ann Surg Oncol,2008,15(7):1862-1870.

[8] PENG ZW,LIN XJ,ZHANG YJ,et al.Radiofrequency ablation versus hepatic for the treatment of hepatocellular carcinomas 2 cm or smaller:a retrospective comparative study[J].Radiology,2012,262(3):1022-1033.

[9]ROSSI S,RAVETT V,ROSA L,et al.Repeated radiofrequency ablation for managenemt of patients with cirrhosis with small hepatocellular carcinoma:a long-term cohort study[J].Hepatology,2011,53(1):136-147.

[10]LLOVET JM,BRUIX J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival[J].Hepatology,2003,37(2):429-442.

[11]JIANG M,MA HB,YANG RM.Efficacy of transarterial chemoembolization in treatment of primary liver cancer:an analysis of 200cases[J].Curr Physician,2012,18(27):70-71.(in Chinese)蒋明,马华兵,杨瑞梅.肝动脉化疗栓塞治疗原发性肝癌200例分析[J].当代医学,2012,18(27):70-71.

[12]FAN WZ,WENG HW,YAO XH,et al.A meta analysis of combination of transcathether arterial chemoembolization and iodine-125seads for treatnaent of hepatocelluar carcinoma[J/CD].J Dig Oncol:Electronic Version,2013,5(2):114-118.(in Chinese)范文哲,翁慧雯,姚学华,等.经肝动脉栓塞化疗联合125I粒子治疗肝细胞癌的Meta分析[J/CD].消化肿瘤杂志:电子版,2013,5(2):114-118.

[13]WANG SS,ZENG QL,CHEN Y,et al.Efficacy of microcatheter superselective catheterization in interventional treatment of small hepatocellular carcinoma[J].The J Pract Med,2012,28(11):1850-1852.(in Chinese)汪盛参,曾庆乐,陈勇,等.微导管超选择插管介入治疗小肝癌的疗效[J].实用医学杂志,2012,28(11):1850-1852.

[14]DAWSON LA,NORMOLLE D,BALTER JM,et al.Analysis of radiation-induced liver disease using the Lyman NTCP model[J].Int J Radiat Oncol Biol Phys,2002,53(4):810-821.

[15]HUANG G,LAI EC,LAN WY,et al.Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV–DNA levels[J].Ann Surg,2013,257(3):490-505.

[16]NOMOTO S,KANDA M,OKAMURA Y,et al.Epidermal growth factor-containing fibulin-like extracellular matrix protein 1,EFEMPl,a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis[J].Ann Surg Oncol,2010,17(3):923-932.

[17]GU H,LI C.Research progress in magnetic nanoparticles for magnetic resonance imaging and targeted therapy of hepatocellular carcinoma[J].J Clin Hepatol,2013,29(10):740-743.(in Chinese)顾晗,李澄.磁性纳米粒子在肝细胞癌磁共振成像及靶向治疗方面的研究进展[J].临床肝胆病杂志,2013,29(10):740-743.

[18] LLOVET JM,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.

[19]CHUNG YH,HAN G,YOON JH,et al.Interim analysis of START:Study in Asia of the combination of TACE(transcatheter arterial chemoembolization)with sorafenib in patients with hepatocellular carcinoma trial[J].Int J Cancer,2013,132(10):2448-2458.

[20]ZHU AX.Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012:current status and future perspectives[J].Semin Oncol,2012,39(4):493-502.

[21]ZHANG Y,ZHANG MJ,JIA ZS.Research advances in cellular immunotherapy for primary hepatocellular carcinoma[J].J Clin Hepatol,2014,30(9):860-864.(in Chinese)张野,张明杰,贾战生.肝细胞癌细胞免疫治疗的研究进展[J].临床肝胆病杂志,2014,30(9):860-864.

[22]ZHAO JF,WANG JN,WU QS,et al.Effects of interferon-Aon recurrence and metastasis of hepatocellular carcinoma after tumor removement[J].J Clin Med Pract,2011,15(11):133-134.(in Chinese)赵家锋,王建南,吴青松,等.干扰素治疗原发性肝癌的临床疗效观察[J].实用临床医药杂志,2011,15(11):133-134.

[23]SHI SL,DONG XM,HU WN,et al.Clinical study of P53 gene therapy on primary hepatocarcinoma[J].Mod J Integr Tradit Chin West Med,2012,21(10):1036-1037.(in Chinese)史守良,董秀敏,胡万宁,等.P53基因治疗原发性肝癌的临床研究[J].现代中西医结合杂志,2012,21(10):1036-1037.

[24]COHEN GS,BLACK M.Multidisciplinary management of hepatocellular carcinoma:a model for therapy[J].J Multidiscip Healthc,2013,6:189-195.

施引文献

资源附件(0)

访问统计